© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
March FDA Pipeline
New approvals and actions in brief
The meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra, Sanofi Pasteur) was approved for protection against meningococcal disease in adolescents and adults aged 11 to 55 years.
FDA approved mometasone (Nasonex, Schering-Plough) for the treatment of nasal polyps in patients aged 18 years and older.